Compare IRTC & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRTC | CPRX |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.4B |
| IPO Year | 2016 | 2006 |
| Metric | IRTC | CPRX |
|---|---|---|
| Price | $104.02 | $31.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 1 |
| Target Price | ★ $197.92 | $35.00 |
| AVG Volume (30 Days) | 472.6K | ★ 1.7M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.71 | 28.24 |
| EPS | N/A | ★ 0.50 |
| Revenue | ★ $747,138,000.00 | $119,072,803.00 |
| Revenue This Year | $19.60 | $9.20 |
| Revenue Next Year | $15.94 | $10.51 |
| P/E Ratio | ★ N/A | $62.77 |
| Revenue Growth | ★ 26.24 | 16.39 |
| 52 Week Low | $100.85 | $19.05 |
| 52 Week High | $210.01 | $32.56 |
| Indicator | IRTC | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.87 | 71.94 |
| Support Level | $101.75 | $31.25 |
| Resistance Level | $121.88 | $32.56 |
| Average True Range (ATR) | 5.32 | 0.04 |
| MACD | -0.31 | -0.14 |
| Stochastic Oscillator | 22.07 | 86.67 |
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.